Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity

BACKGROUND: Carfilzomib (CFZ) is a new proteasome inhibitor used for the treatment of multiple myeloma. Besides heart failure, angina and myocardial ischemia occurred following administration of CFZ, which is not contraindicated in patients with recent myocardial infarction/unstable angina excluded...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen-Scarabelli, Carol, Corsetti, Giovanni, Pasini, Evasio, Dioguardi, Francesco S., Sahni, Gagan, Narula, Jagat, Gavazzoni, Mara, Patel, Hemang, Saravolatz, Louis, Knight, Richard, Raddino, Riccardo, Scarabelli, Tiziano M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514385/
https://www.ncbi.nlm.nih.gov/pubmed/28587834
http://dx.doi.org/10.1016/j.ebiom.2017.05.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514385/
https://www.ncbi.nlm.nih.gov/pubmed/28587834
http://dx.doi.org/10.1016/j.ebiom.2017.05.024

Ejemplares similares